Endocrine Abstracts

Background: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are proven to boost serum testosterone levels in men with type 2 diabetes (T2D) and functional hypogonadism. Nevertheless, the therapeutic potential of this class of drugs on erectile dysfunction (ED) has yet to be entirely studied in men with T2D and functional hypogonadism.Methods: A retrospective cohort study was conducted on 108 outpatients (60 [56, 65] years) with T2D and complaining o...

Background: Erectile dysfunction affects nearly half of men with type 2 diabetes (T2DM), and one-third of diabetic men have hypogonadism1. As an add-on to TRT in hypogonadal men with T2DM, Liraglutide may improve erectile function2, and dulaglutide decreased the incidence of moderate and severe ED in T2DM3.Study aims: To assess the GLP-1RA effect in T2DM men complaining of ED treated with both liraglutide and dulaglutide ...

Tirzepatide, a once-weekly dual co-agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, has been demonstrated to improve glucose control and reduced body weight in different therapeutic approaches. With this rapid review and meta-analysis, we systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin compared to basal insulin plus background treatments titrated rigorously t...